Developer docs
API playgroundTry for free, no card

Search company profiles

Grindeks

Full company profile

uuid003et5k

Namestring
Grindeks
Legal namestring
AS Grindeks
Websiteurl
grindeks.com
Company typeenum
Public
Founded yearint
1946
Descriptiontext

Grindeks (AS Grindeks) is a vertically integrated, publicly listed pharmaceutical manufacturer headquartered in Riga, Latvia, and the leading pharmaceutical company in the Baltic States. Founded in 1946 and listed on the Riga Stock Exchange (rse:GRD1R), the company produces active pharmaceutical ingredients (APIs), generic dosage forms, and original pharmaceutical products covering cardiovascular, central nervous system, oncology, diabetes, and dermatology therapeutic areas. Its portfolio includes more than 100 generic dosage forms alongside original brands Mildronāts (cardiovascular) and Ftorafur (anti-cancer). Grindeks currently manufactures 30 APIs with 36 more in development and runs 122 products through its pipeline.

The company operates three manufacturing sites: the Riga headquarters, the Tallinn Pharmaceutical Factory in Estonia, and HBM Pharma in Slovakia. Distribution runs through wholly-owned subsidiaries across Europe, North America, Asia, and Australia, with products available in all EU member states (16-56 products per country) and exported to more than 100 countries. Regulatory capability is a core competency, evidenced by 23 new EU registrations completed through decentralized procedure in the last three years. Customer relationships span direct deliveries to pharmacies, hospital procurement tenders, and specialized APIs for academic and global health partners (e.g., Wake Forest University School of Medicine, PATH, Instituto Biológico Argentino).

Revenue is generated primarily through pharmaceutical product sales, supplemented in late 2025 by newly introduced CDMO services and out-licensing of final dosage forms — a deliberate shift in business development strategy under CEO Jānis Romanovskis. Therapeutic-area breadth, vertical integration from API to finished form, established distribution infrastructure, and a publicly listed status are the defining structural features of the business. Headcount sits in the 1,001-5,000 employee range, and Grindeks reported €13 million of profit in the January-May 2025 period; pricing is not publicly disclosed.

Short descriptiontext

Grindeks is a publicly listed, vertically integrated Latvian pharmaceutical manufacturer producing APIs, generics, and original drugs across cardiovascular, CNS, oncology, diabetes, and dermatology, distributing to over 100 countries via wholly-owned subsidiaries and a newly launched CDMO business.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersRiga, Latvia
HQ citystring
Riga
HQ countrystring
Latvia
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, active pharmaceutical ingredients, contract development manufacturing, cardiovascular therapeutics, finished dosage forms
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Generic Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sale of original products, generic medicines, and active pharmaceutical ingredients to customers worldwide. Products cover cardiovascular, CNS, oncology, diabetes, and dermatology therapeutic areas.

grindeks.com
2CDMO Services
TypeProfessional Services
Description

Contract manufacturing services for external pharmaceutical clients requiring development and manufacturing capabilities.

grindeks.com
3Out-Licensing Royalties
TypeLicensing Royalties
Description

Licensing of final dosage form products to partners for commercialization in various markets.

grindeks.com
4Hospital Segment Products
TypeOne Time License
Description

Sale of hospital segment medications through subsidiary Kalceks, including direct deliveries to pharmacies in European countries.

grindeks.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Grindeks is a vertically integrated pharmaceutical manufacturer that produces active pharmaceutical ingredients (APIs), generic finished dosage forms, and its own originator brands (notably Mildronāts®/meldonium and Ftorafur®/tegafur) across cardiovascular, CNS, oncology, dermatology, and anti-diabetic therapy areas. Beyond its own product portfolio, the company offers contract development and manufacturing (CDMO) services through subsidiaries including Kalceks, Tallinn Pharmaceutical Factory, and HBM Pharma, and out-licenses proprietary molecules to partners in more than 100 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Profit of 13 million euros achieved in January-May 2025
+2 more records
Product overview1 text field

Grindeks is the leading pharmaceutical company in the Baltic States, operating as a vertically integrated pharmaceutical manufacturer with a portfolio combining original products (Mildronāts®, Ftorafur®), generic medicines (over 100 forms), and active pharmaceutical ingredients (30 currently produced, 36 in development). The company specializes in cardiovascular, central nervous system, oncological, diabetes, and dermatology treatments. Under new CEO leadership, Grindeks has expanded into CDMO services and out-licensing, while its subsidiary Kalceks serves the hospital segment. Products are available in all EU countries and over 100 countries worldwide, with subsidiaries operating in Europe, North America, Asia, and Australia.

Product and service1 record
1Mildronāts® (meldonium)
CategoryProprietary originator brand
Description

Grindeks' proprietary originator brand of meldonium, indicated in cardiovascular and central nervous system therapy areas; sold as a finished dosage form across multiple international markets under the Grindeks label.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2010-08-17
Description

Grindeks agreed on closer cooperation with Latvian Institute of Organic Synthesis for joint development initiatives. Expansion of cooperation confirmed through senior management meetings. Professor Ivars Kalviņš from IOS received St. Georgi medal in 2004. Researcher Maija Dambrova from IOS received Grindelis Medal for pharmacological research on Mildronate.

2Tallinas farmaceitiskā rūpnīca (Tallinn Pharmaceutical Factory)
Strategic tierCoreTypeOthers
Description

Manufacturing facility in Estonia that is part of Grindeks Group, strengthening group's global operations and production capacity outside Latvia.

grindeks.com
Strategic tierCoreTypeOthers
Description

Manufacturing facility in Slovakia that is part of Grindeks Group, strengthening group's global operations and ability to adapt to demand in various markets.

Strategic tierCoreTypeOthers
Description

Subsidiary company providing hospital segment medications, offering products through direct deliveries to pharmacies in European countries.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Respected USA research center selected Grindeks oxytocin for international research project. Contract concluded for supply of active pharmaceutical ingredient oxytocin.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Argentinian pharmaceutical company that proposed Grindeks for joint international project 'Oxytocin in Uniject' conducted by PATH for global healthcare.

7PATH
Strategic tierMajorTypeStrategic or Co-development Partner
Description

International nonprofit organization conducting global health initiative 'Oxytocin in Uniject' for which Grindeks supplies oxytocin API.

grindeks.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Grindeks

Generic Pharmaceuticalsgrindeks.com

Grindeks is a publicly listed, vertically integrated Latvian pharmaceutical manufacturer producing APIs, generics, and original drugs across cardiovascular, CNS, oncology, diabetes, and dermatology, distributing to over 100 countries via wholly-owned subsidiaries and a newly launched CDMO business.

What Grindeks does

Grindeks (AS Grindeks) is a vertically integrated, publicly listed pharmaceutical manufacturer headquartered in Riga, Latvia, and the leading pharmaceutical company in the Baltic States. Founded in 1946 and listed on the Riga Stock Exchange (rse:GRD1R), the company produces active pharmaceutical ingredients (APIs), generic dosage forms, and original pharmaceutical products covering cardiovascular, central nervous system, oncology, diabetes, and dermatology therapeutic areas. Its portfolio includes more than 100 generic dosage forms alongside original brands Mildronāts (cardiovascular) and Ftorafur (anti-cancer). Grindeks currently manufactures 30 APIs with 36 more in development and runs 122 products through its pipeline.

The company operates three manufacturing sites: the Riga headquarters, the Tallinn Pharmaceutical Factory in Estonia, and HBM Pharma in Slovakia. Distribution runs through wholly-owned subsidiaries across Europe, North America, Asia, and Australia, with products available in all EU member states (16-56 products per country) and exported to more than 100 countries. Regulatory capability is a core competency, evidenced by 23 new EU registrations completed through decentralized procedure in the last three years. Customer relationships span direct deliveries to pharmacies, hospital procurement tenders, and specialized APIs for academic and global health partners (e.g., Wake Forest University School of Medicine, PATH, Instituto Biológico Argentino).

Revenue is generated primarily through pharmaceutical product sales, supplemented in late 2025 by newly introduced CDMO services and out-licensing of final dosage forms — a deliberate shift in business development strategy under CEO Jānis Romanovskis. Therapeutic-area breadth, vertical integration from API to finished form, established distribution infrastructure, and a publicly listed status are the defining structural features of the business. Headcount sits in the 1,001-5,000 employee range, and Grindeks reported €13 million of profit in the January-May 2025 period; pricing is not publicly disclosed.

Grindeks firmographics

Firmographics
Name
Grindeks
Legal name
AS Grindeks
Website
https://grindeks.com
Company type
Public
Founded year
1946
Operating status
Operating
Headcount range
251–500 employees
Short description
Grindeks is a publicly listed, vertically integrated Latvian pharmaceutical manufacturer producing APIs, generics, and original drugs across cardiovascular, CNS, oncology, diabetes, and dermatology, distributing to over 100 countries via wholly-owned subsidiaries and a newly launched CDMO business.
Ownership category
akta.pro rank

Grindeks industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Generic pharmaceuticals
  • Active pharmaceutical ingredients
  • Contract development manufacturing
  • Cardiovascular therapeutics
  • Finished dosage forms

Where Grindeks is headquartered

Location

Headquarters

HQ city
Riga
HQ country
Latvia
HQ region
Europe

Offices3 records

Markets served

Grindeks business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Sale of original products, generic medicines, and active pharmaceutical ingredients to customers worldwide. Products cover cardiovascular, CNS, oncology, diabetes, and dermatology therapeutic areas.
  2. CDMO Services: Contract manufacturing services for external pharmaceutical clients requiring development and manufacturing capabilities.
  3. Out-Licensing Royalties: Licensing of final dosage form products to partners for commercialization in various markets.
  4. Hospital Segment Products: Sale of hospital segment medications through subsidiary Kalceks, including direct deliveries to pharmacies in European countries.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Grindeks product offering

Product offering

Core offering

Grindeks is a vertically integrated pharmaceutical manufacturer that produces active pharmaceutical ingredients (APIs), generic finished dosage forms, and its own originator brands (notably Mildronāts®/meldonium and Ftorafur®/tegafur) across cardiovascular, CNS, oncology, dermatology, and anti-diabetic therapy areas. Beyond its own product portfolio, the company offers contract development and manufacturing (CDMO) services through subsidiaries including Kalceks, Tallinn Pharmaceutical Factory, and HBM Pharma, and out-licenses proprietary molecules to partners in more than 100 countries.

Product overview

Grindeks is the leading pharmaceutical company in the Baltic States, operating as a vertically integrated pharmaceutical manufacturer with a portfolio combining original products (Mildronāts®, Ftorafur®), generic medicines (over 100 forms), and active pharmaceutical ingredients (30 currently produced, 36 in development). The company specializes in cardiovascular, central nervous system, oncological, diabetes, and dermatology treatments. Under new CEO leadership, Grindeks has expanded into CDMO services and out-licensing, while its subsidiary Kalceks serves the hospital segment. Products are available in all EU countries and over 100 countries worldwide, with subsidiaries operating in Europe, North America, Asia, and Australia.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mildronāts® (meldonium) Grindeks' proprietary originator brand of meldonium, indicated in cardiovascular and central nervous system therapy areas; sold as a finished dosage form across multiple international markets under the Grindeks label.

Quantifiable outcome

  • Profit of 13 million euros achieved in January-May 2025
  • +2 more outcomes

Companies that use Grindeks

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Grindeks technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Grindeks partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and major.

  • Latvian Institute of Organic Synthesis (IOS)coreStrategic or Co-development Partner · 17 August 2010Grindeks agreed on closer cooperation with Latvian Institute of Organic Synthesis for joint development initiatives. Expansion of cooperation confirmed through senior management meetings. Professor Ivars Kalviņš from IOS received St. Georgi medal in 2004. Researcher Maija Dambrova from IOS received Grindelis Medal for pharmacological research on Mildronate.
  • Tallinas farmaceitiskā rūpnīca (Tallinn Pharmaceutical Factory)coreOthersManufacturing facility in Estonia that is part of Grindeks Group, strengthening group's global operations and production capacity outside Latvia.
  • HBM PharmacoreOthersManufacturing facility in Slovakia that is part of Grindeks Group, strengthening group's global operations and ability to adapt to demand in various markets.
  • KalcekscoreOthersSubsidiary company providing hospital segment medications, offering products through direct deliveries to pharmacies in European countries.
  • Wake Forest University School of MedicinemajorStrategic or Co-development PartnerRespected USA research center selected Grindeks oxytocin for international research project. Contract concluded for supply of active pharmaceutical ingredient oxytocin.
  • Instituto Biológico Argentino S.A.I.C. (BIOL)majorStrategic or Co-development PartnerArgentinian pharmaceutical company that proposed Grindeks for joint international project 'Oxytocin in Uniject' conducted by PATH for global healthcare.
  • PATHmajorStrategic or Co-development PartnerInternational nonprofit organization conducting global health initiative 'Oxytocin in Uniject' for which Grindeks supplies oxytocin API.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Grindeks competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Grindeks social profiles

Digital presence

Grindeks financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Grindeks leadership team

Management profile

Number of profiles

Profiles2 records

Grindeks subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Grindeks funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Grindeks M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grindeks

What does Grindeks do?

Grindeks is a vertically integrated pharmaceutical manufacturer that produces active pharmaceutical ingredients (APIs), generic finished dosage forms, and its own originator brands (notably Mildronāts®/meldonium and Ftorafur®/tegafur) across cardiovascular, CNS, oncology, dermatology, and anti-diabetic therapy areas. Beyond its own product portfolio, the company offers contract development and manufacturing (CDMO) services through subsidiaries including Kalceks, Tallinn Pharmaceutical Factory, and HBM Pharma, and out-licenses proprietary molecules to partners in more than 100 countries.

Is Grindeks a public or private company?

Grindeks is a public company. It is classified as public and is currently operating.

When was Grindeks founded?

Grindeks was founded in 1946. It employs 251 to 500 people.

Where is Grindeks based?

Grindeks is headquartered in Riga, Latvia, in the Europe region.

How does Grindeks make money?

Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are CDMO Services, out-Licensing Royalties and hospital Segment Products.

Does Grindeks have an API?

No public API is recorded for Grindeks.

What industry is Grindeks in?

Grindeks's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Eng.lsm.lv«Asiņainie rubļi». No viskija līdz zālēm: Latvijas eksports uz agresorvalstīm lielākais Baltijā – pusmiljards eiro 5 mēnešosLatvia's exports to Russia and Belarus exceeded 500 million euros in the first five months of 2026, making it the largest exporter among Baltic states despite the ongoing war in Ukraine. Pharmaceuticals, alcoholic beverages, and textiles constitute the main export categories, with two sector flagships—AS "Grindeks" and AS "Olpha"—publicly identified as continuing exports to aggressor states. The new coalition government has pledged to halt all trade with Russia and Belarus, though no concrete implementation plans have been announced.MorningstarBaltics leading pharmaceutical company Grindeks expands to new export markets worldwideGrindeks, a Latvian pharmaceutical company, will deliver products to Panama this year, expanding its export reach. The company already exports to over 100 countries, including Chile, Mexico, Australia, and Europe, and supplies WHO-prequalified injections to African nations. It aims to rank among the top 100 global pharmaceutical companies.PR NewswireLatvian pharmaceutical manufacturing company Grindeks opens new subsidiaries worldwideLatvian pharmaceutical company Grindeks has established 28 subsidiaries across Europe and other countries including Canada and the United States as part of its strategy to expand export markets and reinforce its position in global pharmaceutical markets. The company has developed 30 new products over the past three years and currently has more than 100 pharmaceutical formulations in development across therapeutic areas including central nervous system, cardiovascular, diabetes, dermatology, and oncology. Operations are planned to commence in additional countries including Austria, Switzerland, Japan, and Korea in coming years.PR NewswireLatvian pharmaceutical manufacturing company Grindeks opens new subsidiaries worldwideLatvian pharmaceutical company Grindeks has established 28 subsidiaries across Europe, North America, and other regions to expand its global export markets and product reach. The company is currently developing over 100 pharmaceutical formulations and has submitted 30 new products for registration in the past three years.PR NewswireLa empresa letona de fabricación farmacéutica Grindeks abre nuevas filiales en todo el mundoGrindeks, a leading Baltic pharmaceutical manufacturer headquartered in Latvia, has been expanding its global presence by establishing 28 subsidiaries across Europe and other countries, including Canada and the United States, with operations gradually launched since 2022. The company is developing 30 new products and has over 100 pharmaceutical formulations in development across therapeutic areas including central nervous system, cardiovascular, diabetes, dermatological, and oncological treatments. Grindeks plans to continue its international expansion into Austria, Switzerland, Japan, and Korea in the coming year, exporting products to more than 100 countries worldwide.PR NewswireLettischer Pharmahersteller Grindeks eröffnet weltweit neue NiederlassungenGrindeks, a leading Latvian pharmaceutical company, is expanding its global footprint by establishing new subsidiaries across Europe and beyond, having already opened 28 subsidiaries in various countries. The company has also submitted 30 new products for approval in the past three years and has over 100 pharmaceutical formulations in development. This expansion supports Grindeks' strategy to diversify export markets and strengthen its position in key therapeutic areas including cardiology, oncology, diabetes, and dermatology.PR NewswireLa société pharmaceutique lettonne Grindeks ouvre de nouvelles filiales dans le monde entierGrindeks, the leading pharmaceutical company in Latvia and the Baltic states, has expanded its global footprint by establishing 28 subsidiaries across Europe, North America, and Asia since 2022, with recent operations launched in Greece, Canada, the US, Ireland, and France, and planned entries into Japan, Korea, Switzerland, and Austria. The company reports significant R&D activity with 30 new products submitted for regulatory approval and over 100 pharmaceutical formulations under development targeting cardiovascular, CNS, diabetes, dermatology, and oncology therapeutic areas. Grindeks exports products to more than 100 countries, employs over 1,380 professionals, and positions itself as an international pharmaceutical group offering full product lifecycle services from research through manufacturing and sales.PR NewswireGrindeks erweitert sein Angebot an generischen Medikamenten und seine Aktivitäten auf internationalen MärktenGrindeks, the leading pharmaceutical company in the Baltic states, announced plans to significantly expand its range of generic medicines and international market activities, targeting CNS disorders, cardiovascular diseases, diabetes, and oncology treatments. The company plans to register 18 generic medicines in 2022, while its subsidiary Kalceks will file for approval of 10 hospital-segment medicines, with further expansion including new subsidiaries in the USA, Switzerland, and additional EU countries. Grindeks currently exports products to 103 countries and manufactures 25 pharmaceutical active substances, with 46 new substances in development.PR NewswireGrindeks Expands Range of Generic Medicines and Activities in International MarketsGrindeks, the leading pharmaceutical enterprise in the Baltic States, announced plans to expand its range of generic medicines and international market activities, focusing on CNS diseases, cardiovascular diseases, diabetes, and oncological diseases. The company plans to apply for registration of 18 generic medicines in 2022, while its subsidiary Kalceks will apply for 10 medicines in the hospital segment. Grindeks exported products to 103 countries in 2021 and will open new subsidiary enterprises in the USA, Switzerland, and EU countries this year.PR NewswireGrindeks Group closes 2021 with record high turnover of EUR 231.1 millionGrindeks Group reported record-high financial results for 2021, achieving a turnover of EUR 231.1 million and a profit of EUR 41.0 million, both representing significant year-over-year growth. The company expanded its global footprint by exporting products to 103 countries, with notable sales increases in markets such as Portugal, Brazil, and Ukraine.